Literature DB >> 19487285

ERG is a megakaryocytic oncogene.

Samira Salek-Ardakani1, Gil Smooha, Jasper de Boer, Neil J Sebire, Michelle Morrow, Liat Rainis, Sandy Lee, Owen Williams, Shai Izraeli, Hugh J M Brady.   

Abstract

Ets-related gene (ERG) is a member of the ETS transcription factor gene family located on Hsa21. ERG is known to have a crucial role in establishing definitive hematopoiesis and is required for normal megakaryopoiesis. Truncated forms of ERG are associated with multiple cancers such as Ewing's sarcoma, prostate cancer, and leukemia as part of oncogenic fusion translocations. Increased expression of ERG is highly indicative of poor prognosis in acute myeloid leukemia and ERG is expressed in acute megakaryoblastic leukemia (AMKL); however, it is unclear if expression of ERG per se has a leukemogenic activity. We show that ectopic expression of ERG in fetal hematopoietic progenitors promotes megakaryopoiesis and that ERG alone acts as a potent oncogene in vivo leading to rapid onset of leukemia in mice. We observe that the endogenous ERG is required for the proliferation and maintenance of AMKL cell lines. ERG also strongly cooperates with the GATA1s mutated protein, found in Down syndrome AMKL, to immortalize megakaryocyte progenitors, suggesting that the additional copy of ERG in trisomy 21 may have a role in Down syndrome AMKL. These data suggest that ERG is a hematopoietic oncogene that may play a direct role in myeloid leukemia pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487285     DOI: 10.1158/0008-5472.CAN-09-0075

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 2.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

3.  ERG Is a Useful Immunohistochemical Marker to Distinguish Leukemia Cutis From Nonneoplastic Leukocytic Infiltrates in the Skin.

Authors:  Bin Xu; Daisy Naughton; Klaus Busam; Melissa Pulitzer
Journal:  Am J Dermatopathol       Date:  2016-09       Impact factor: 1.533

4.  MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Authors:  Y Huang; J A I Thoms; M L Tursky; K Knezevic; D Beck; V Chandrakanthan; S Suryani; J Olivier; A Boulton; E N Glaros; S R Thomas; R B Lock; K L MacKenzie; J H Bushweller; J W H Wong; J E Pimanda
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

5.  The ERGonomics of hematopoietic stem cell self-renewal.

Authors:  Scott A Lacadie; Leonard I Zon
Journal:  Genes Dev       Date:  2011-02-15       Impact factor: 11.361

6.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Authors:  Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

7.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

8.  Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Authors:  Ying Xie; Mia Lee Koch; Xin Zhang; Melanie J Hamblen; Frank J Godinho; Yuko Fujiwara; Huafeng Xie; Jan-Henning Klusmann; Stuart H Orkin; Zhe Li
Journal:  Stem Cells       Date:  2017-04-24       Impact factor: 6.277

Review 9.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.